Regulatory BMS bags first approval for myeloma CELMoD Zenbexus PharmaphorumBristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.HematologyRead full story pharminent August 14, 2026 (Last updated: August 21, 2026) Pharmaphorum Bristol Myers Squibb’s CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma. Hematology Read full story Post navigation Previous: PTC Therapeutics Acquires Sangamo’s Fabry Disease Gene TherapyNext: BMS Wins First FDA Approval for CELMoD Class With Zenbexus in Multiple Myeloma Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026